Oracit
RxNorm 544550· CITRIC ACID AND SODIUM CITRATE· ORAL
CMP Pharma, Inc.
Indications and usage
INDICATIONS ORACIT ® is indicated for the treatment of metabolic acidosis. This solution is also useful in conditions where long term maintenance of alkaline urine is needed (e.g. uric acid and cystine calculi of the urinary tract). ORACIT ® is also effective in treatment for acidosis of certain renal tubular disorders.
Dosage and administration
DOSAGE AND ADMINISTRATION The dose of ORACIT ® is 10 to 30 mL, diluted with water, after meals and at bedtime. The dose should be titrated to achieve desired effects.
Contraindications
CONTRAINDICATIONS ORACIT ® is contraindicated in patients with severe renal impairment, oliguria or azotemia, untreated Addison's disease, adynamia episodica hereditaria, acute dehydration, heat cramp, anuria, severe myocardial damage, and hyperkalemia.
Adverse events
Most frequently reported events (FDA FAERS). Report frequency does not imply causation.
- fatigue3
- blood count abnormal2
- nausea2
- osteomyelitis2
- pneumonia2
- product packaging confusion2
- renal failure2
- abdominal pain upper1
- abnormal behaviour1
- anaemia1
- asthma1
- back disorder1
- back pain1
- bedridden1
- bone cancer1
- cataract operation1
Adverse reactions (label)
ADVERSE REACTIONS Citrate solution is generally well tolerated when given in recommended doses when the patient has normal renal functions. To report suspected adverse reactions, contact CMP Pharma, Inc., toll free at 1-844-321-1443 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
View more: Full FDA label on DailyMed →Label effective 20231207